TCM Biotech International (TPE:4169) Shares Outstanding (EOP): 66.4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4169 TCM Biotech International Corp TPE:4169
52 GF Score
Price NT$153.50
GF Value NT$42.31
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is TCM Biotech International Shares Outstanding (EOP)?

TCM Biotech International TPE:4169 -2.23% 52 Shares Outstanding (EOP) is 66.4 Mil as of Mar. 2026. GuruFocus rates TPE:4169 with a GF Score™ of 52/100 and a GF Value™ of NT$42.31 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. TCM Biotech International's shares outstanding for the quarter that ended in Mar. 2026 was 66.4 Mil.

TCM Biotech International's quarterly shares outstanding stayed the same from Dec. 2025 (66.4 Mil) to Mar. 2026 (66.4 Mil).

TCM Biotech International's annual shares outstanding increased from Dec. 2024 (59.0 Mil) to Dec. 2025 (66.4 Mil). It means TCM Biotech International issued new shares from Dec. 2024 to Dec. 2025 .


TCM Biotech International  (TPE:4169) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


TCM Biotech International Shares Outstanding (EOP) Related Terms


TCM Biotech International Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for TCM Biotech International's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TCM Biotech International Shares Outstanding (EOP) Chart

TCM Biotech International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.13 51.13 59.05 59.05 66.43

TCM Biotech International Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.05 59.05 59.51 66.43 66.43

TPE:4169 vs VRTX, REGN, RVMD: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, TCM Biotech International's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TCM Biotech International Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TCM Biotech International's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where TCM Biotech International's Shares Outstanding (EOP) falls into.


TPE:4169
52GF Score
TCM Biotech International Corp TPE:4169
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TCM Biotech International Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 66.4 Mil mean?
TCM Biotech International (TPE:4169) has a Shares Outstanding (EOP) of 66.4 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on TCM Biotech International and its competitors.
Is TCM Biotech International's Shares Outstanding (EOP) too high?
TCM Biotech International's current Shares Outstanding (EOP) is 66.4 Mil. Overall, TCM Biotech International has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TCM Biotech International's Shares Outstanding (EOP) compare to VRTX and REGN?
TCM Biotech International's Shares Outstanding (EOP) of 66.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on TCM Biotech International and its competitors. TCM Biotech International's current Shares Outstanding (EOP) is 66.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TCM Biotech International stock overvalued right now?
Based on GuruFocus' analysis, TCM Biotech International (TPE:4169) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$42.31, compared to a current price of NT$153.50 — trading 262.8% above its estimated fair value. The current Shares Outstanding (EOP) is 66.4 Mil. TCM Biotech International's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For TCM Biotech International (TPE:4169), the current Shares Outstanding (EOP) is 66.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TCM Biotech International (TPE:4169) Overvalued in 2026?

Based on GuruFocus' analysis, TCM Biotech International stock appears to be overvalued. The current stock price of NT$153.50 is trading 262.8% above its estimated GF Value™ of NT$42.31. GuruFocus considers TCM Biotech International to be Significantly Overvalued.

Key valuation signals for TPE:4169:

  • Shares Outstanding (EOP): 66.4 Mil
  • GF Value™: NT$42.31 vs. price of NT$153.50 (262.8% above fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the TPE:4169 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TCM Biotech International Business Description

Address No. 97, Section 1, Xintai 5th Road, 24th Floor-8, Xizhi District, Neihu District, Taipei, TWN, 221416
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in research and development of new biotech drugs, development of microbial strain cultivation and fermentation technology, biotechnology services, wholesale of medical equipment, and sales of functional foods. Its products includes medical equipment, medical testing platform, medical drugs, and others. The Group has two reportable segments: Segment A and Segment B. Segment A is the functional foods segment, while Segment B is the pharmaceuticals segment. It derives maximum revenue from pharmaceuticals segment. Geographically, the company operates in Taiwan and Other countries, of which it generates maximum revenue from Taiwan.
52GF Score

Get the complete analysis for TPE:4169

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$153.50
Price
NT$42.31
GF Value